Home > News > The Evolution of Retinal Laser Technology and Retinal Photocoagulation as Therapeutic Modality
Retina/Vitreous
Read Time: 2 mins

The Evolution of Retinal Laser Technology and Retinal Photocoagulation as Therapeutic Modality

Published Online: May 22nd 2012 European Ophthalmic Review, 2012;6(3):185–9 DOI: http://doi.org/10.17925/EOR.2012.06.03.185
Authors: Kfir Azoulay, Pazit Pianka, Anat Loewenstein
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

The effect of thermal insult to ocular tissue was first recorded in Western literature over two millennia ago. During the early scientific period and the ensuing eras, our understanding of this phenomenon, as well as our ability to accurately deliver dose-controlled therapeutic thermal energy to retinal tissue, have improved greatly. Since their commercial introduction in 1970, ophthalmic photocoagulation laser systems have been playing a cardinal role in the treatment and/or management of various ocular pathologies, predominantly though not limited to, retinal pathologies. Seminal studies, such as the Diabetic Retinopathy Study (DRS) and Early Treatment Diabetic Retinopathy Study (ETDRS), have solidified the role of such tools in the ophthalmologist’s therapeutic armamentarium; and to this day, as either stand-alone treatment or in combination with pharmacological agents, retinal laser therapy is recognised as the ‘gold standard’ for treating diabetic macular oedema (DME) and proliferative diabetic retinopathy (PDR). The continuous elucidation of the role that the retinal pigmented epithelium (RPE) plays in the emergence of retinal pathologies has prompted researchers and clinicians to further investigate selective RPE treatments – featuring significantly reduced or altogether devoid of collateral thermal damage to inner neural retinal structures with limited regenerative capacity. The convergence of electronic dosimetry, diagnostics imaging and new therapeutic laser modalities into a singular entity may serve as the technological platform for successfully employing such therapies in the near future.

Keywords

Ophthalmic lasers, history of lasers, laser technology, laser evolution, thermal damage to retina, photocoagulation, multi-wavelength lasers, Diabetic Retinopathy Study (DRS), Early Treatment Diabetic Retinopathy Study (ETDRS), scanning lasers, selective retina therapy (SRT), image-guided laser therapy

Article:

One of the earliest recorded descriptions of thermal energy effect on ocular tissue in general and the retina in particular is ascribed to the Greek scholar and philosopher Plato,1 who admonished of the deleterious impact of gazing directly at a solar eclipse. However, it was not until the 17th century AD that the first scientific-like description of a central scotoma resulting from solar thermal insult to the macula was produced by Swiss scholar Theophilus Bonetus.2

The advent of the telescope in the 17th century, along with the subsequent increase in astronomy and stargazing, led to several contemporaneous reports of inadvertent retinal coagulation resulting from inappropriate utilisation of this novel technology, particularly when employed for directly viewing the sun or sun-related events. With the invention of the ophthalmoscope by Hermann von Helmholtz in 1851 (although, for the sake of historical accuracy, the ophthalmoscope had been invented four years earlier by the English Charles Babbage without Von Helmholtz’s knowledge), such reported cases could be further elucidated by direct ophthalmoscopic observation and correlation of clinical manifestations to the morphological changes in the retinal tissue subjected to thermal insult.

A series of animal experimentations on the impact of focused sunlight and retinal damage was pioneered by Czerny in 1867.3 Additional work also involving artificial light (produced from carbon arc rods), was conducted by Deutschman and Widemark in the decades that followed.

The first extensive clinical study on the impact of thermal damage to the retina (‘Solar Retinopathy’) was conducted by Birch-Hirschfeld in 1912.4 Birch-Hirschfeld was the first scientist to postulate that the humanly visible portion of the solar spectrum was responsible for the retinal changes occurring from eclipse blinding. However, it was Verhoeff and Bell who in 1916 concluded5 that solar retinopathy resulted from thermal damage, rather than from photochemical effects of light on the retina.

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:
Disclosure

Kfir Azoulay and Pazit Pianka are employed by Lumenis, manufacturer of ophthalmic lasers. Anat Loewenstein is a paid consultant to Lumenis.

Correspondence

Kfir Azoulay, Lumenis Holland, Locatellikade 1, 1076 AZ Amsterdam, The Netherlands. E: kazoulay@lumenis.com

Support

The publication of this article was supported by Lumenis.

Received

2012-06-15T00:00:00

References

  1. Plato. Phaedo. Jowett B, trans. Lawrence, KS: Digireads.com Publishing; 2006.
  2. Hamm, H, Zentralskotom nach Sonneblendung, dissertation, Hamburg, 1947.
  3. L'Esperance FA, Ophthalmic Lasers, St Louis, US: C.V. Mosby, 1977;3.
  4. Birch-Hirshlfeld B, Zum kapitel der sonnenblendung des Auges, Zeitschrift für Augenheilkunde, 1912;28:324–47,444–9 and 509–30.
  5. Verhoeff FH, Bell L, Thermic Effects of Radiant Energy upon the Retina P, The Pathological Effects of Radiant Energy on the Eye, Boston, US: Proc Am Acad Arts Sci, 1916;51(13):697–9.
  6. Cordes FC, A type of foveo-macular retinitis observed in the US navy, Am J Ophth, 1946;27:803–16.
  7. Smith H, Actinic macular retinal pigment degeneration, US Naval Med Bull, 1944;42:675–80.
  8. Churchill MH, Diatary deficiency among prisoners of war, J Roy Army Med Corps, 1945;35:294–8.
  9. Dekking HM, Tropical nutritiona amblyopia (“camp eyes”), Ophthalmologica, 1947;113:63–92.
  10. Meyer-Schwickerath G, Light coagulation, St Louis, US: CV Mosby, 1960.
  11. L'Esperance FA Jr, An opthalmic argon laser photocoagulation system: design, construction, and laboratory investigations, Trans Am Ophthalmol Soc, 1968;66:827–904.
  12. L’Esprance FA Jr, Trans-spectral organic dye laser photocoagulation, Trans Am Ophthalmol Soc, 1985;83:82–113.
  13. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings, Ophthalmology, 1978;85(1):82–106.
  14. Fine SL, Patz A, Ten years after the Diabetic Retinopathy Study, Ophthalmology, 1987;94(7):739–40.
  15. Early Treatment Diabetic Retinopathy Study Research Group, Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2, Ophthalmology, 1987;94:761–74.
  16. Early Treatment Diabetic Retinopathy Study Research Group, Techniques for scatter and local photocoagulation treatment of diabetic retinopathy. Early Treatment Diabetic Retinopathy Study Report Number 3, Int Ophthalmol Clin, 1987;27:254–64.
  17. Early Treatment Diabetic Retinopathy Study Research Group, Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 4, Int Ophthalmol Clin, 1987;27:265–72.
  18. Early Treatment Diabetic Retinopathy Study Research Group, Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS Report Number 7, Ophthalmology, 1991;98:741–56.
  19. Early Treatment Diabetic Retinopathy Study Research Group, Early photocoagulation for diabetic retinopathy. ETDRS Report Number 9, Ophthalmology, 1991;98:766–85.
  20. Early Treatment Diabetic Retinopathy Study Research Group, Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report Number 19, Arch Ophthalmol, 1995;113:1144–55.
  21. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report Number 1, Arch Ophthalmol, 1985;103:1796–806.
  22. Fankhauser F 2nd, Giger H, Niederer P, Seiler T, Transpupillary laser phototherapy of tumors and vascular anomalies of retina and choroid: theoretical approach and clinical implications, Technol Health Care, 2000;8(2):93–112.
  23. Balles MW, Puliafito CA, D'Amico DJ, et al., Semiconductor diode laser photocoagulation in retinal vascular disease, Ophthalmology, 1990;97:1553–61.
  24. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Fong DS, Strauber SF, Aiello LP, et al., Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema, Arch Ophthalmol, 2007;125(4):469–80.
  25. Diabetic Retinopathy Clinical Research Network, The course of response to focal/grid photocoagulation for diabetic macular edema, Retina, 2009;29(10):1436–43.
  26. Scott IU, Danis RP, Bressler SB, et al., Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center-involved diabetic macular edema, Retina, 2009;29(5):613–7.
  27. Diabetic Retinopathy Clinical Research Network, A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema, Ophthalmology, 2008;115(9):1447–9.
  28. Lauer AK, Bressler NM, Edwards AR, et al., Frequency of intraocular pressure increase within days after intravitreal triamcinolone injections in the diabetic retinopathy clinical research network, Arch Ophthalmol, 2011;129(8):1097–9.
  29. Elman MJ, Bressler NM, Qin H, et al., Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema, Ophthalmology, 2011;118(4):609–14.
  30. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, et al., Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema, Ophthalmology, 2010;117(6):1064–77.e35
  31. Luttrull JK, Sramek C, Palanker D, et al., Long-term safety, high-resolution imaging, and tissue temperature modeling of subvisible diode micropulse photocoagulation for retinovascular macular edema, Retina, 2012;32(2):375–86.
  32. Lavinsky D, Cardillo JA, Melo LA Jr, et al., Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema, Invest Ophthalmol Vis Sci, 2011;52(7):4314–23.
  33. Blumenkranz MS, Yellachich D, Andersen DE, et al., Semiautomated patterned scanning laser for retinal photocoagulation, Retina, 2006;26:370–6.
  34. Jain A, Blumenkranz MS, Paulus Y, et al., Effect of pulse duration on size and character of the lesion in retinal photocoagulation, Arch Ophthalmol, 2008;126:78–85.
  35. Nagpal M, Marlecha S, Nagpal K, Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser, Retina, 2010;30:452–8.
  36. Roider J, Michaud NA, Flotte TJ, Birngruber R, Response of the retinal pigment epithelium to selective photocoagulation, Arch Ophthalmol, 1992;110:1786–92.
  37. Roider J, Hillenkamp F, Flotte F, Birngruber R, Microphotocoagulation: selective effects of short laser pulses, Proc Natl Acad Sci U S A, 1993;90:8643–7.
  38. Roider J, El Hifnawi ES, Birngruber R, Bubble formation as primary interaction mechanism in retinal laser exposure with 200-ns laser pulses, Lasers Surg Med, 1998;22(4):240–8.
  39. Roider J, Brinkmann R, Wirbelauer C, et al., Subtreshold (retinal pigment epithelium) photocoagulation in macular diseases: a pilot study, Br J Ophthalmol, 2000;84(1):40–7.
  40. Roider J, Liew, SHM, Klatt C, et al., Selective retina therapy (SRT) for clinically significant diabetic macular edema, Graefes Arch Clin Exp Ophthalmol, 2010;248:1263–72.

Further Resources

Share this Article
Related Content In Retina/Vitreous
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72